Current use and future potential role of retinoids in dermatology.

Abstract:

:Since their introduction 15 years ago, retinoids have been increasingly used for topical and systemic treatment of psoriasis and other hyperkeratotic and parakeratotic skin disorders, keratotic genodermatoses, severe acne and acne-related dermatoses, and also for therapy and/or chemoprevention of skin cancer and other neoplasia. Oxidative metabolites of vitamin A (retinol) are natural retinoids present at low levels in the peripheral blood. Synthetic retinoids are classified into 3 generations including nonaromatic, monoaromatic and polyaromatic compounds. They are detectable in plasma 30-60 minutes after systemic administration, and reach maximum concentrations 2 to 4 hours later. Elimination half-life is 10 to 20 hours for isotretinoin, 80 to 175 days for etretinate and 2 to 4 days for, trans-acitretin; the latter, however, partially converts into etretinate. Retinoid concentrations in skin are rather low in contrast to subcutaneous fat tissue. Intracellularly, retinoids interact with cytosolic proteins and specific nuclear receptors. Two classes of nuclear receptors have been suggested to mediate retinoid activity at the molecular level, RARs and RXRs. The expression of retinoid receptors is tissue specific; skin mainly espresses RAR gamma and RXR alpha. Retinoids affect epidermal cell growth and differentiation as well as sebaceous gland activity and exhibit immunomodulatory and anti-inflammatory properties. Current retinoid research targets the development of receptor-selective retinoids for tailoring and/or improving their therapeutic profile. Currently, tretinoin is used systemically for acute promyelocytic leukaemia, etretinate and acitretin for psoriasis and related disorders, as well as other disorders of keratinisation and isotretinoin for seborrhoea, severe acne, rosacea and acneiform dermatoses. Systemic retinoids are also applied for chemoprevention of epithelial skin cancer and cutaneous T cell lymphoma. The major adverse effect of retinoids is teratogenicity; all other adverse effects are dose-dependent and controllable. Contraception is, therefore, essential during retinoid treatment in women of child-bearing age. Clinical monitoring requires physical examination for adverse effects every 3 to 4 weeks and proper laboratory investigations, also including analysis of retinoid bioavailability in selected cases. Topical retinoids are rapidly developing at present and seem promising for the future; their clinical application includes acne, aging, photodamage, precanceroses, skin cancer and disorders of skin pigmentation. The development of receptor-specific retinoids for topical treatment of psoriasis and/or acne may lead to interesting new compounds based on our current concepts of retinoid function.

journal_name

Drugs

journal_title

Drugs

authors

Orfanos CE,Zouboulis CC,Almond-Roesler B,Geilen CC

doi

10.2165/00003495-199753030-00003

subject

Has Abstract

pub_date

1997-03-01 00:00:00

pages

358-88

issue

3

eissn

0012-6667

issn

1179-1950

journal_volume

53

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Clinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.

    abstract::Drug-drug interactions (DDIs) occur commonly and may lead to severe adverse drug reactions if not handled appropriately. Considerable information to support clinical decision making regarding potential DDIs is available in the literature and through various systems providing electronic decision support for healthcare ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-017-0729-x

    authors: Lund M,Petersen TS,Dalhoff KP

    更新日期:2017-05-01 00:00:00

  • Severe asthma: prevention is better than cure.

    abstract::Asthmatic patients during sympton-free periods almost invariably have abnormalities in lung mechanics and gas exchange. Tentacious secretions and mucosal thickening exaggerate maldistribution of ventilation and cause flow limitation in small airways. Hence, the maximal expiratory flow volume loop in these patients wil...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-197816030-00007

    authors: Goldstein RS,Slutsky AS,Rebuck AS

    更新日期:1978-09-01 00:00:00

  • Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?

    abstract::The cardiovascular and cardiorenal disease continuum comprises the transition from cardiovascular risk factors to endothelial dysfunction and atherosclerosis, to clinical complications such as myocardial infarction (MI) and stroke, to the development of persistent target-organ damage and, ultimately, to chronic conges...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11537910-000000000-00000

    authors: Werner C,Pöss J,Böhm M

    更新日期:2010-07-09 00:00:00

  • Airway and lung remodelling in chronic pulmonary obstructive disease: a role for muscarinic receptor antagonists?

    abstract::Lung tissue remodelling in chronic inflammatory lung diseases has long been regarded as a follow-up event to inflammation. Recent studies have indicated that, although airway and lung tissue remodelling is often independent of inflammation, it precedes or causes inflammation. None of the available therapies has a sign...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0319-0

    authors: Roth M

    更新日期:2015-01-01 00:00:00

  • Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders.

    abstract::Goserelin is a gonadotrophin-releasing hormone (GnRH) analogue which, during continuous administration, down-regulates the pituitary-ovarian gonadal axis and reduces levels of the gonadotrophins, luteinising hormone and follicle-stimulating hormone. In women, this results in suppression of ovarian steroidogenesis and ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199651020-00009

    authors: Perry CM,Brogden RN

    更新日期:1996-02-01 00:00:00

  • Azimilide.

    abstract::Azimilide is a potassium channel antagonist that, in contrast to existing class III antiarrhythmic agents, blocks both the rapidly (I(Kr)) and slowly (I(Ks)) activating components of the delayed rectifier potassium current. In animal and clinical studies, azimilide prolonged repolarisation by increasing the action pot...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-200059020-00016

    authors: Clemett D,Markham A

    更新日期:2000-02-01 00:00:00

  • 5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo.

    abstract:UNLABELLED:5-Methoxypsoralen, a naturally occurring linear furocoumarin, has been successfully used in combination with ultraviolet (UV) A irradiation [psoralen plus UV (PUVA)] to manage psoriasis and vitiligo. In patients and volunteers, PUVA 5-methoxypsoralen causes a dose-related increase in cutaneous photosensitivi...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856040-00015

    authors: McNeely W,Goa KL

    更新日期:1998-10-01 00:00:00

  • Alirocumab: First Global Approval.

    abstract::Alirocumab (Praluent®) is a fully human monoclonal antibody developed by Regeneron Pharmaceuticals and Sanofi that has been approved in the US as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolaemia (HeFH) or clinical atherosclerotic car...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0469-8

    authors: Markham A

    更新日期:2015-09-01 00:00:00

  • Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension.

    abstract::Mild to moderate hypertension still remains poorly controlled. This relates to multiple factors including low antihypertensive efficacy of single drug therapies reluctance of primary care physicians to modify/titrate initially chosen therapy to obtain target blood pressure, and poor compliance with medication. Several...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161070-00004

    authors: Ruzicka M,Leenen FH

    更新日期:2001-01-01 00:00:00

  • Glycaemia control in diabetes mellitus. Towards the normal profile?

    abstract::The Diabetes Control and Complications Trial and the Stockholm Study have conclusively demonstrated that improving the blood glucose control in patients with insulin-dependent diabetes mellitus (IDDM) reduces the risk of developing retinopathy, nephropathy and neuropathy. Each patient with IDDM should be carefully eva...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199447040-00005

    authors: Zimmerman BR

    更新日期:1994-04-01 00:00:00

  • Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

    abstract::Coronary arterial thrombolysis is becoming an established treatment of acute myocardial infarction. If given early enough, it recanalises occluded coronary arteries, salvages myocardial function and reduces mortality. A reduction of mortality in patients with acute myocardial infarction has now been demonstrated for s...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198938030-00003

    authors: Collen D,Lijnen HR,Todd PA,Goa KL

    更新日期:1989-09-01 00:00:00

  • Digoxin use in congestive heart failure. Current status.

    abstract::The use of digitalis in congestive heart failure with normal sinus rhythm is still debated. While older uncontrolled, withdrawal studies from 1969 to 1983 provided incomplete data, with poorly documented clinical status and poor haemodynamic and exercise data, some patients did improve clinically when digitalis treatm...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199855060-00002

    authors: Riaz K,Forker AD

    更新日期:1998-06-01 00:00:00

  • Transdermal Nicotine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation.

    abstract::Transdermal nicotine delivery systems are a cigarette smoking cessation aid designed to deliver nicotine into the systemic circulation via the skin. The partial replacement of plasma nicotine, which would have otherwise been obtained from cigarettes, reduces the severity of nicotine withdrawal symptoms, and so allows ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199244030-00011

    authors: Palmer KJ,Buckley MM,Faulds D

    更新日期:1992-09-01 00:00:00

  • Postoperative ileus: progress towards effective management.

    abstract::The pathogenesis of postoperative ileus (PI) is multifactorial, and includes activation of inhibitory reflexes, inflammatory mediators and opioids (endogenous and exogenous). Accordingly, various strategies have been employed to prevent PI. As single-modality treatment, continuous postoperative epidural analgesia incl...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262180-00004

    authors: Holte K,Kehlet H

    更新日期:2002-01-01 00:00:00

  • Cannabinoids: Current and Future Options to Treat Chronic and Chemotherapy-Induced Neuropathic Pain.

    abstract::Increases in cancer diagnosis have tremendous negative impacts on patients and their families, and major societal and economic costs. The beneficial effect of chemotherapeutic agents on tumor suppression comes with major unwanted side effects such as weight and hair loss, nausea and vomiting, and neuropathic pain. Che...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01132-x

    authors: Blanton HL,Brelsfoard J,DeTurk N,Pruitt K,Narasimhan M,Morgan DJ,Guindon J

    更新日期:2019-06-01 00:00:00

  • Brexpiprazole: First Global Approval.

    abstract::Brexpiprazole (Rexulti®) is an atypical antipsychotic that has been developed by Otsuka Pharmaceutical Co. Ltd and H. Lundbeck A/S as an oral treatment for several psychiatric disorders. Brexpiprazole is a novel serotonin-dopamine activity modulator that acts as a partial agonist of serotonin 1A (5-HT1A) and dopamine ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0462-2

    authors: Greig SL

    更新日期:2015-09-01 00:00:00

  • Treating ocular hypertension to reduce glaucoma risk: when to treat?

    abstract::When to treat the patient who presents with ocular hypertension has been a question that has 'stumped' the ophthalmic community for decades. Population-based studies and intervention trials have provided the basis for understanding why we consider treating such patients. Although the EGPS (European Glaucoma Prevention...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666080-00001

    authors: Higginbotham EJ

    更新日期:2006-01-01 00:00:00

  • Antidepressants for the treatment of insomnia : a suitable approach?

    abstract::The popularity of antidepressants in the treatment of insomnia is not supported by a large amount of convincing data, but rather by opinions and beliefs of the prescribing physicians on the advantages of these agents compared with drugs acting on the benzodiazepine receptor or other drugs used for the treatment of ins...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/0003495-200868170-00001

    authors: Wiegand MH

    更新日期:2008-01-01 00:00:00

  • Clinical evidence with montelukast in the management of chronic childhood asthma.

    abstract:OBJECTIVE:The aim of this article is to review data on the efficacy and safety of montelukast in the treatment of children with asthma. METHODOLOGY:Available published literature, including published abstracts, is reviewed. RESULTS:In patients aged 6 to 14 years with asthma (n = 27), montelukast 5mg demonstrated a si...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200059001-00005

    authors: Becker A

    更新日期:2000-01-01 00:00:00

  • Histamine and leukotriene receptor antagonism in the treatment of allergic rhinitis: an update.

    abstract::Allergic rhinitis represents a global health burden. The disease can seriously affect quality of life and is associated with multiple co-morbidities. Histamine and leukotrienes are important pro-inflammatory mediators in nasal allergic inflammation. Their actions on target cells are mediated through specific receptors...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767180-00006

    authors: Van Hoecke H,Vandenbulcke L,Van Cauwenberge P

    更新日期:2007-01-01 00:00:00

  • Fetal pharmacotherapy.

    abstract::Rapid progress has recently been encountered in pharmacologically treating the unborn baby. This unique area of drug therapy raises new methodological and ethical questions. This article is a systematic review of known modalities of fetal pharmacotherapy, and aims to highlight essential principles, difficulties and co...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262050-00004

    authors: Koren G,Klinger G,Ohlsson A

    更新日期:2002-01-01 00:00:00

  • Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.

    abstract::Alectinib (Alecensa(®)) is a second-generation, orally active, potent and highly selective inhibitor of anaplastic lymphoma kinase (ALK). Alectinib is approved for the treatment of ALK fusion-gene positive, unresectable, advanced or recurrent non-small cell lung cancer (NSCLC) in Japan, where it has been given orphan ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0329-y

    authors: McKeage K

    更新日期:2015-01-01 00:00:00

  • Remission, a therapeutic goal in inflammatory arthropathies? Clinical data from adalimumab studies.

    abstract::In recent years, there have been major advances in the management of rheumatoid arthritis (RA), leading to the development of tumour necrosis factor (TNF) antagonists. With these agents, it is possible to arrest joint damage and, by treating early in the disease course, to prevent joint damage. It is also now thought ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666140-00001

    authors: Montecucco C

    更新日期:2006-01-01 00:00:00

  • Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus?

    abstract::Results from the United Kingdom Prospective Diabetes Study showed that intensive treatment of type 2 (non-insulin-dependent) diabetes mellitus, with sulphonylureas or insulin, significantly reduced microvascular complications but did not have a significant effect on macrovascular complications after 10 years. Insulin ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200060050-00004

    authors: Campbell IW

    更新日期:2000-11-01 00:00:00

  • Trimetrexate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of Pneumocystis carinii pneumonia.

    abstract::Trimetrexate is a folinic acid analogue structurally related to methotrexate, whose primary mechanism of action is believed to be inhibition of dihydrofolate reductase. This reduces the production of DNA and RNA precursors and leads to cell death. Trimetrexate is lipophilic and can passively diffuse across cell membra...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199549040-00007

    authors: Fulton B,Wagstaff AJ,McTavish D

    更新日期:1995-04-01 00:00:00

  • MenB-FHbp Meningococcal Group B Vaccine (Trumenba®): A Review in Active Immunization in Individuals Aged ≥ 10 Years.

    abstract::MenB-FHbp (bivalent rLP2086; Trumenba®) is a recombinant protein-based vaccine targeting Neisseria meningitidis serogroup B (MenB), which has recently been licensed in the EU for active immunization to prevent invasive disease caused by MenB in individuals ≥ 10 years of age. The vaccine, which contains a variant from ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-018-0869-7

    authors: Shirley M,Taha MK

    更新日期:2018-02-01 00:00:00

  • Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia.

    abstract::Benzbromarone1 is a benzofuran derivative which lowers serum urate and increases urinary urate excretion in normal, hyperuricaemic and gouty subjects. In open short- and long-term studies benzbromarone reduced serum uric acid levels by one-third to one-half and maintained its effectiveness for periods of up to 8 years...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197714050-00002

    authors: Heel RC,Brogden RN,Speight TM,Avery GS

    更新日期:1977-11-01 00:00:00

  • Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke.

    abstract::Stroke is the third most common cause of death in the US. Primary prevention of stroke can be achieved by control of risk factors including hypertension, diabetes mellitus, elevated cholesterol levels and smoking. Approximately one-third of all ischaemic strokes occur in patients with a history of stroke or transient ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565040-00003

    authors: Weinberger J

    更新日期:2005-01-01 00:00:00

  • Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations.

    abstract::As a consequence of disparities in access to and utilization of preventative healthcare, the incidence and death rates from cervical cancer remain substantial in the face of indisputable evidence that screening saves lives. While disparities persist, there will be an urgent need for research into the treatment of adva...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0481-z

    authors: Longoria TC,Tewari KS

    更新日期:2015-11-01 00:00:00

  • HMG-CoA reductase inhibitors in chronic heart failure: potential mechanisms of benefit and risk.

    abstract::HMG-CoA reductase inhibitors (statins) have been shown to reduce mortality and cardiovascular morbidity in patients with hyperlipidaemia and those with coronary artery disease. However, evidence for statin treatment in patients with chronic heart failure (CHF) remains a subject of debate. Patients with heart failure w...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666020-00002

    authors: Laufs U,Custodis F,Böhm M

    更新日期:2006-01-01 00:00:00